Ernexa Therapeutics, Inc. (ERNA)
4.30
+0.14
(+3.24%)
USD |
NASDAQ |
Sep 14, 10:49
Ernexa Therapeutics Enterprise Value : 0.1951M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 0.1951M |
| September 10, 2026 | 0.0254M |
| September 09, 2026 | 0.0254M |
| September 08, 2026 | 0.2243M |
| September 04, 2026 | 0.3647M |
| September 03, 2026 | 0.6221M |
| September 02, 2026 | 0.6338M |
| September 01, 2026 | 0.4115M |
| August 31, 2026 | 0.6689M |
| August 28, 2026 | 0.6689M |
| August 27, 2026 | 0.862M |
| August 26, 2026 | 1.043M |
| August 25, 2026 | 1.084M |
| August 24, 2026 | 1.213M |
| August 21, 2026 | 1.008M |
| August 20, 2026 | 0.6104M |
| August 19, 2026 | 0.5051M |
| August 18, 2026 | 0.2945M |
| August 17, 2026 | 0.0722M |
| August 14, 2026 | 0.3179M |
| August 13, 2026 | 0.353M |
| August 12, 2026 | 0.4934M |
| August 11, 2026 | 0.4583M |
| August 10, 2026 | 0.6221M |
| August 07, 2026 | 0.2477M |
| Date | Value |
|---|---|
| August 06, 2026 | 0.4232M |
| August 05, 2026 | 0.119M |
| August 04, 2026 | 0.4934M |
| August 03, 2026 | -0.6415M |
| July 31, 2026 | -0.8404M |
| July 30, 2026 | -0.6181M |
| July 29, 2026 | -0.6883M |
| July 28, 2026 | -0.4543M |
| July 27, 2026 | -0.0916M |
| July 24, 2026 | -0.0799M |
| July 23, 2026 | -0.0097M |
| July 22, 2026 | 0.5285M |
| July 21, 2026 | 0.6338M |
| July 20, 2026 | 1.675M |
| July 17, 2026 | 2.833M |
| July 16, 2026 | 3.652M |
| July 15, 2026 | 3.196M |
| July 14, 2026 | 2.412M |
| July 13, 2026 | 1.804M |
| July 10, 2026 | 2.412M |
| July 09, 2026 | 2.260M |
| July 08, 2026 | 2.026M |
| July 07, 2026 | 2.576M |
| July 06, 2026 | 2.857M |
| July 02, 2026 | 2.658M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cerenome, Inc. | 8.453M |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
| Alnylam Pharmaceuticals, Inc. | 32.94B |
| Anika Therapeutics, Inc. | 266.01M |
| Savara, Inc. | 945.99M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.009M |
| Total Expenses (Quarterly) | 4.009M |
| EPS Diluted (Quarterly) | -3.396 |
| Earnings Yield | -440.1% |
| Normalized Earnings Yield | -436.53 |